# Tango Therapeutics (TNGX) — Analyst Forecast

TNGX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tngx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 1 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $35.00 | $47.25 | $68.00 | 4 |

Last price $22.70 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 18, 2026 | HC Wainwright & Co. | Maintained | Buy | $68.00 |
| Aug 12, 2026 | Guggenheim | Maintained | Buy | $35.00 |
| Jul 17, 2026 | Mizuho | Maintained | Outperform | $40.00 |
| Jul 15, 2026 | JP Morgan | Initiated Coverage | Overweight | $46.00 |
| Jun 29, 2026 | Canaccord Genuity | Maintained | Buy | $46.00 |
| Jun 26, 2026 | Jefferies | Upgraded | Hold → Buy | $60.00 |
| Jun 11, 2026 | Canaccord Genuity | Maintained | Buy | $42.00 |
| Jun 9, 2026 | Canaccord Genuity | Maintained | Buy | $42.00 |
| Jun 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $66.00 |
| Jun 8, 2026 | Leerink Partners | Maintained | Outperform | $69.00 |
| May 15, 2026 | Piper Sandler | Downgraded | Overweight → Neutral | $24.00 |
| May 15, 2026 | Mizuho | Maintained | Outperform | $30.00 |
| May 14, 2026 | Wedbush | Maintained | Outperform | $33.00 |
| May 14, 2026 | Leerink Partners | Maintained | Outperform | $55.00 |
| May 14, 2026 | Jefferies | Downgraded | Buy → Hold | $27.00 |
| Apr 27, 2026 | Stifel | Maintained | Buy | $40.00 |
| Apr 2, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $30.00 |
| Mar 11, 2026 | Mizuho | Maintained | Outperform | $20.00 |
| Mar 9, 2026 | Stifel | Maintained | Buy | $24.00 |
| Mar 6, 2026 | HC Wainwright & Co. | Maintained | Buy | $27.00 |

## Frequently Asked Questions

### What is the price target for TNGX stock?

The average 12-month analyst price target for Tango Therapeutics (TNGX) is $47.25, with a high estimate of $68.00 and a low of $35.00, across 4 analysts.

### Is TNGX a buy, sell, or hold?

Analysts covering Tango Therapeutics currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for TNGX?

The average price target of $47.25 implies 108.15% upside from the last price of $22.70.

### What is the latest analyst rating on TNGX?

On Aug 18, 2026, HC Wainwright & Co. maintained Tango Therapeutics at Buy with a price target of $68.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).